Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 14-03-2004
  • E-pubdatum
  • 14-03-2004
  • Bron
  • Medische Oncologie

Toevoeging van aprepitant aan 5HT3/dexamethason bij hoog emetogene chemotherapie

Op grond van de thans ter beschikking staande resultaten kan worden aanbevolen aprepitant vanaf de eerste kuur hoog emetogene chemotherapie toe te voegen aan een 5HT3- antagonist- plus dexamethasoncombinatie.


  1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. ‘Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapyinduced nausea and vomiting. Results from a randomized, doubleblind, placebo-controlled trial in Latin America’. Cancer 2003;97:3090-8.
  2. Hesketh PJ, Grunberg SM, Gralla RJ, et al. ‘The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: a multinational, randomized, double-blind, placebo controlled trial in patients receiving high-dose cisplatin’. J Clin Oncol 2003;21: 4112-9.
  3. De Wit R, Herrstedt J, Rapoport B, et al. ‘Addition of the oral NK1 antagonist aprepitant to standard antemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy’. J Clin Oncol 2003;21:4105-11. 
  4. De Wit R. ‘Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer 2003;88:1823-7. 5. 
  5. Wit de R, van den Berg H, Burghouts J, et al. ‘Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles’. Br J Cancer 1998;77:1487-91. 
  6. Cocquyt V, Van Belle S, Reinhardt RR, et al. ‘Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatininduced emesis’. Eur J Cancer 2001;37:835-42.
  7. Italian Group for Antiemetic Research. ‘Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer’. N Engl J Med 1995; 332:1-5.
  8. Latreille J, Pater J, Johnston D, et al. ‘Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy’. J Clin Oncol 1998;16:1174-8.
  9. Goedhals L, Heron J-F, Kleisbauer J-P et al. ‘Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebocontrolled, comparative study’. Ann Oncol 1998;9:661-6.
  10. Tsukada H, Hirose T, Yokoyama A, et al. ‘Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis’. Eur J Cancer 2001;37:2398-404.
  11. U.S. Food and Drug Administration. Aprepitant materials for FDA submission. March 6, 2003. Available onlineat:
  12. Martin AR, Carides AD, Pearson JD, et al. ‘Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomized study of the NK1 antagonist aprepitant’. Eur J Cancer 2003;39:1395-401. 
  13. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.